骨髓增生异常综合征与慢性粒单核细胞白血病异基因造血干细胞移植:国际专家小组推荐
国际专家小组针对骨髓增生异常综合征(MDS)和慢性粒单核细胞白血病(CMML)的异基因造血干细胞移植(HSCT)制定推荐。基于修订版国际预后评分系统(IPSS-R)和HCT合并症指数(HCT-CI)评估移植资格,推荐高危或低危伴不良遗传学特征、严重血细胞减少及高输血负荷的适合患者接受HSCT,并对移植前细胞减灭治疗、预处理方案选择、供者淋巴细胞输注(DLI)预防及复发后处理给出建议。
要点
- IPSS-R和HCT-CI是评估MDS/CMML患者HSCT资格的关键临床变量。
- 适合的高危IPSS-R或低危伴不良遗传学特征、严重血细胞减少及高输血负荷患者是HSCT候选者。
- 骨髓原始细胞≥10%的患者建议移植前细胞减灭治疗;高危复发患者推荐预防性DLI。
核心结论
- 适合的高危IPSS-R或低危IPSS-R伴不良遗传学特征、严重血细胞减少及高输血负荷的MDS/CMML患者是HSCT的候选者。
- 基于高龄、高HCT-CI、极差细胞遗传学和分子特征及高IPSS-R评分的极高移植风险患者,标准HSCT治愈机会低,应考虑在研究中治疗。
- 骨髓原始细胞≥10%的患者建议移植前细胞减灭治疗;对高强度预处理有禁忌者应考虑减低强度预处理;高危复发患者推荐预防性DLI;移植后6个月后复发建议免疫调节(DLI或二次HSCT)。
研究设计与样本
- 由欧洲血液和骨髓移植学会、欧洲白血病网、血液和骨髓移植临床试验组及国际骨髓增生异常综合征基金会活跃成员组成的国际专家小组制定推荐。
主要发现
- 疾病风险按修订版国际预后评分系统(IPSS-R)评分,合并症按HCT合并症指数(HCT-CI)分级,被视为HSCT资格的相关临床变量。
- 基于高龄、高HCT-CI、极差细胞遗传学和分子特征及高IPSS-R评分的极高MDS移植风险评分患者,标准HSCT治愈机会低。
- 前瞻性随机临床试验证据不支持对最佳高强度预处理方案给出具体推荐。
关键数值与推荐
- 适合的高危IPSS-R患者及低危IPSS-R伴不良遗传学特征、严重血细胞减少和高输血负荷的患者是HSCT候选者。
- 骨髓原始细胞≥10%的患者建议移植前细胞减灭治疗。
- 对高强度预处理有禁忌的患者应考虑减低强度预处理。
- 高危复发患者推荐预防性供者淋巴细胞输注(DLI)策略。
- 移植后6个月后复发建议免疫调节(DLI策略或二次HSCT)。
临床怎么用
- 采用IPSS-R和HCT-CI评估MDS/CMML患者的移植资格。
- 极高移植风险评分患者标准HSCT治愈机会低,考虑在研究中治疗。
- 骨髓原始细胞≥10%者移植前给予细胞减灭治疗;高强度预处理有禁忌者考虑减低强度预处理。
- 高危复发患者推荐预防性DLI;移植后6个月后复发建议DLI或二次HSCT。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
An international expert panel, active within the European Society for Blood and Marrow Transplantation, European LeukemiaNet, Blood and Marrow Transplant Clinical Trial Group, and the International Myelodysplastic Syndromes Foundation developed recommendations for allogeneic hematopoietic stem cell transplantation (HSCT) in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Disease risks scored according to the revised International Prognostic Scoring System (IPSS-R) and presence of comorbidity graded according to the HCT Comorbidity Index (HCT-CI) were recognized as relevant clinical variables for HSCT eligibility. Fit patients with higher-risk IPSS-R and those with lower-risk IPSS-R with poor-risk genetic features, profound cytopenias, and high transfusion burden are candidates for HSCT. Patients with a very high MDS transplantation risk score, based on combination of advanced age, high HCT-CI, very poor-risk cytogenetic and molecular features, and high IPSS-R score have a low chance of cure with standard HSCT and consideration should be given to treating these patients in investigational studies. Cytoreductive therapy prior to HSCT is advised for patients with ≥10% bone marrow myeloblasts. Evidence from prospective randomized clinical trials does not provide support for specific recommendations on the optimal high intensity conditioning regimen. For patients with contraindications to high-intensity preparative regimens, reduced intensity conditioning should be considered. Optimal timing of HSCT requires careful evaluation of the available effective nontransplant strategies. Prophylactic donor lymphocyte infusion (DLI) strategies are recommended in patients at high risk of relapse after HSCT. Immune modulation by DLI strategies or second HSCT is advised if relapse occurs beyond 6 months after HSCT.
引用
- de Witte T, Bowen D, Robin M, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017. PMID: 28096091. doi:10.1182/blood-2016-06-724500
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。